$ONCO #Oncopeptides AB Oncopeptides - Karyopharm making progress: Karyopharm reported its Q1’20 and sales of XPOVIO ~70 sales reps enough to tackle the US market We expect accelerated FDA approval in Q4’20e https://t.co/AJY4uJWvhc #equity #stocks https://t.co/pW8PhDj8bb